WHO Drug Information Vol. 19, No. 3, 2005
(2005; 72 pages)

Personal Perspectives
	Unfinished business: clinical pharmacology and world health
Safety and Efficacy Issues
	Transdermal fentanyl: abuse by adolescents
	Safety of fentanyl transdermal patches
	Rosiglitazone: decreased high-density lipoprotein cholesterol
	Ibuprofen: Stevens-Johnson syndrome
	Stringent conditions for COX-2 Inhibitors
	Sildenafil, tadalafil and vardenafil: eye problems reported
	Nesiritide: safety report and measures
	Mifepristone, sepsis and blood infection
	Mifepristone: revised safety information
	Suicidality with SSRIs in adults
	Ezetimibe and muscle disorders
	Pathological gambling with cabergoline
	Icodextrin peritoneal dialysis solution: falsely elevated blood glucose readings
	New requirements for pseudoephedrine products
	Efalizumab: warning of thrombocytopenia
	Antiretrovirals: HIV, hepatic impairment and HBV/HCV
Herbal Medicines
	Monograph for cultivation of herbal antimalarial: Artemisia annua
	Ayurvedic medicines and heavy metals
	National policy on regulation of herbal medicines
	Regulatory guidelines for complementary medicines
Regulatory Action and News
	Hydromorphone extended release suspended
	New drug safety initiative
	Deregistration of thioridazine
	Caution on self medication
	European marketing authorizations
	Tigecycline: first-in-class antibiotic approved
Essential Medicines
	Highlights of the 14th Model List of Essential Medicines
		Methadone and buprenorphine
		Mifepristone with misoprostol
	WHO Model List of Essential Medicines
Access to Medicines
	Intellectual property protection: impact on public health
The International Pharmacopoeia
	International Pharmacopoeia: fourth edition in development
Recommended International Nonproprietary Names: List 54

WHO Drug Information Vol. 19, No. 3, 2005

WHO Drug Information

e-mail table of contents
and subscriptions
available at:

http://www.who.int/druginformation